肾复康片联合氯沙坦治疗慢性肾小球肾炎的临床研究  

Clinical study on Shenfukang Tablets combined with losartan in treatment of chronic glomerulonephritis

作　　者：王军涛[1] 魏晓颖[1] 王晓阳[2] WANG Jun-tao;WEI Xiao-ying;WANG Xiao-yang(Department of Renal Rheumatology Immunology,the First People’s Hospital of Shangqiu,Shangqiu 476100,China;Department of Nephrology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]商丘市第一人民医院肾病风湿免疫科,河南商丘476100 [2]郑州大学第一附属医院肾病内二科,河南郑州450052

出　　处：《现代药物与临床》2023年第4期924-928,共5页Drugs & Clinic

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20191505)。

摘　　要：目的探讨肾复康片联合氯沙坦钾片治疗慢性肾小球肾炎的临床疗效。方法选取2020年12月—2022年6月在商丘市第一人民医院的收治的122例慢性肾小球肾炎患者,根据随机数字表法将全部患者分为对照组和治疗组,每组各61例。对照组口服氯沙坦钾片,1片/次,1次/d。治疗组在对照组治疗的基础上口服肾复康片,6片/次,3次/d。两组持续治疗12周。观察两组的临床疗效,比较两组血尿、蛋白尿的转阴时间以及血清血肌酐(Scr)、尿白蛋白排泄率(UAER)、尿24h尿蛋白定量(24hUpro)、尿红细胞、尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、尿激酶型纤溶酶原激活物受体(uPAR)、β_(2)-微球蛋白(β_(2)-MG)、白细胞诱素-1(Lkn-1)、白细胞介素-13(IL-13)、基质金属蛋白酶-9(MMP-9)水平。结果治疗后,治疗组的总有效率为95.08%,明显高于对照组的83.61%(P<0.05)。治疗后,治疗组血尿、蛋白尿转阴时间均明显短于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清Scr、UAER和尿24 h Upro、尿红细胞明显低于治疗前(P<0.05),且治疗组血清Scr、UAER和尿24 h Upro、尿红细胞低于对照组,差异有统计学意义(P<0.05)。治疗后,两组的NGAL、uPAR、β_(2)-MG水平低于治疗前(P<0.05),且治疗组的NGAL、uPAR、β_(2)-MG低于对照组(P<0.05)。治疗后,两组血清Lkn-1、IL-13、MMP-9水平低于对照组(P<0.05);治疗组的血清Lkn-1、IL-13、MMP-9水平低于对照组(P<0.05)。结论肾复康片联合治疗氯沙坦钾片治疗慢性肾小球肾炎的疗效确切,能减轻临床症状、炎症反应和肾功能损伤,安全性良好。Objective To investigate the clinical effect of Shenfukang Tablets combined with Losartan Potassium Tablets in treatment of chronic glomerulonephritis.Methods Patients(122 cases)with chronic glomerulonephritis in the First People’s Hospital of Shangqiu from December 2020 to June 2022 were divided into control and treatment groups according to the random number table method,and each group had 61 cases.Patients in the control group were po administered with Losartan Potassium Tablets,1 tablet/time,once daily.Patients in the treatment group were po administered with Shenfukang Tablet on the basis of the control group,6 tablets/time,three times daily.Patients in two groups were treated for 12 weeks.After treatment,the clinical efficacies were evaluated,and the conversion time of hematuria and proteinuria,the levels of Scr,UAER,24 h Upro,urinary erythrocytes,NGAL,uPAR,andβ_(2)-MG,Lkn-1,IL-13,and MMP-9 in two groups were compared.Results After treatment,the total effective rate of the treatment group was 95.08%,which was significantly higher than 83.61%of the control group(P<0.05).After treatment,the time of turning negative of hematuria and albuminuria in the treatment group was significantly shorter than that in the control group(P<0.05).After treatment,the serum Scr,UAER,urine 24h Upro,and urine red blood cells in two groups were significantly decreased(P<0.05),and the serum Scr,UAER,urine 24h Upro,and urine red blood cells in the treatment group were lower than those in the control group,with statistically significant difference (P < 0.05). After treatment, the levels of NGAL, uPAR, and β_(2)-MG was lower than that before treatment (P < 0.05), and the levels of NGAL, uPAR, and β_(2)-MG was lower than that in the control group (P < 0.05). Conclusion Shenfukang Tabletscombined with Losartan Potassium Tablets has definite curative effect in treatment of chronic glomerulonephritis, can alleviate clinical symptoms, inflammatory reaction, and renal damage with good safety.

关 键 词：肾复康片 氯沙坦钾片 慢性肾小球肾炎 蛋白尿转阴时间 中性粒细胞明胶酶相关脂质运载蛋白 β_(2)-微球蛋白 

分 类 号：R983[医药卫生—药品]